62806-33-1

Basic information

• Product Name: 3-(5-PHENYL-FURAN-2-YL)-ACRYLIC ACID
• Synonyms: ASISCHEM Z25585;AKOS BB-8376;3-(5-PHENYL-FURAN-2-YL)-ACRYLIC ACID;RARECHEM AL BK 0884;3-(5-PHENYL-2-FURYL)-2-PROPENOIC ACID;(E)-3-(5-phenylfuran-2-yl)acrylic acid
• CAS NO: 62806-33-1
• Molecular Formula: C₁₃H₁₀O₃
• Molecular Weight: 214.22
• Mol File: 62806-33-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(5-PHENYL-FURAN-2-YL)-ACRYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-PHENYL-FURAN-2-YL)-ACRYLIC ACID(62806-33-1)
• EPA Substance Registry System: 3-(5-PHENYL-FURAN-2-YL)-ACRYLIC ACID(62806-33-1)

Safety Data

• Hazardous Substances Data: 62806-33-1(Hazardous Substances Data)

Upstream product

• 22078-90-6 2-hydroxymethyl-5-phenylfuran 
• 34265-60-6 (E)-3-(5-Phenyl-furan-2-yl)-acrylic acid ethyl ester 
• 1018586-19-0 2-(chloromethyl)-5-phenylfuran 
• 1899-24-7 5-bromo-2-furancarboxaldehyde 
• 98-80-6 phenylboronic acid 
• 100-34-5 benzene diazonium chloride 
• 98-01-1 furfural 
• 39511-08-5 (E)-3-(2-furanyl)-2-propenal 
• 62-53-3 aniline 
• 13803-39-9 5-phenylfuran-2-carbaldehyde 
• 141-82-2 malonic acid 

Downstream Products

• 912369-19-8 tert-butyl (3S)-3-[(7-cyano-2-phenylfuro[3,2-c]pyridin-4-yl)amino]piperidine-1-carboxylate 
• 912369-18-7 4-chloro-2-phenylfuro[3,2-c]pyridine-7-carbonitrile 
• 912369-17-6 7-bromo-2-phenylfuro[3,2-c]pyridin-4(5H)-one 
• 188437-82-3 2-phenylfuro[3,2-c]pyridin-4(5H)-one 
• 111252-83-6 (E)-N,N-Dimethyl-3-(5-phenyl-furan-2-yl)-acrylamide 
• 111252-42-7 (E)-3-(5-Phenyl-furan-2-yl)-acryloyl chloride 
• 129626-54-6 4-[(E)-2-(5-Phenyl-furan-2-yl)-vinyl]-benzoic acid ethyl ester 
• 40025-25-0 (E)-5-phenyl-2-(2-phenylvinyl)furan 
• 107450-78-2 3,6-Dichloro-2-phenylthieno<3,2-b>furan-5-carboxylic acid chloride 

Relevant articles and documents

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors

Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from different chemical scaffolds have been developed and evaluated in clinical trials in combination with chemotherapeutics and radiation treatment. Scaffold morphing of thiophene carboxamide ureas (TCUs), such as AZD7762 (1) and a related series of triazoloquinolines (TZQs), led to the identification of fused-ring bicyclic CHK1 inhibitors, 7-carboxamide thienopyridines (7-CTPs), and 7-carboxamide indoles. X-ray crystal structures reveal a key intramolecular noncovalent sulfur-oxygen interaction in aligning the hinge-binding carboxamide group to the thienopyridine core in a coplanar fashion. An intramolecular hydrogen bond to an indole NH was also effective in locking the carboxamide in the preferred bound conformation to CHK1. Optimization on the 7-CTP series resulted in the identification of lead compound 44, which displayed respectable drug-like properties and good in vitro and in vivo potency.

SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS

This invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.

Structure-activity relationships of novel anti-malarial agents part 8. Effect of different central aryls in biarylacryloylaminobenzophenones on antimalarial activity

Replacement of the 2,5-disubstituted furyl residue present in the known antimalarial agents 8 by other aryl residues resulted in a more or less reduced antimalarial activity in most cases. The only exemption was the 2,4-thienylene compound 11a displaying activity with an IC50 value of 120 nM. In conclusion, the 2,5-furylene compound 8e remains to represent the most active antimalarial agent in this series of farnesyltransferase inhibitors.